Radiographic Assessment of Deproteinized Porcine Versus Bovine Bone Mineral in Sinus Augmentation (NCT07182929) | Clinical Trial Compass
CompletedNot Applicable
Radiographic Assessment of Deproteinized Porcine Versus Bovine Bone Mineral in Sinus Augmentation
China56 participantsStarted 2024-01-01
Plain-language summary
The goal of this retrospective study is to compare the radiographic outcomes of deproteinized porcine bone mineral (DPBM) and deproteinized bovine bone mineral (DBBM) following lateral sinus floor augmentation (LSFA) with simultaneous implant placement. The main questions it aims to answer are:
Does DPBM show greater graft resorption than DBBM at 6 months postoperatively? Do both materials achieve comparable bone quality and osseointegration outcomes despite differences in resorption rates?
This is a retrospective, single-center cohort study. Participants included 56 patients (56 sinuses) who underwent LSFA with either DPBM (test group, n=28) or DBBM (control group, n=28) and had complete cone-beam CT scans taken preoperatively, immediately postoperatively, and at 6 months post-surgery. Radiographic parameters such as bone height, augmentation volume, and bone texture features were analyzed to evaluate graft stability and new bone formation.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Aged between 18 and 80 years;
✓. Single or multiple missing teeth in the posterior maxilla with a healing period of at least 3 months;
✓. Complete baseline data and surgical records;
✓. Underwent LSFA with simultaneous placement of a single implant, grafted exclusively with either DBBM (Bio-Oss®, 0.25-1.0 mm, Geistlich Pharma AG, Wolhusen, Switzerland) or DPBM (THE Graft®, 0.25-1.0 mm, Purgo Biologics, Seoul, Korea);
✓. Available CBCT images obtained preoperatively (T0), immediately postoperatively (T1), and at 6 months postoperatively (T2);
✓. RBH ≤6 mm shown by CBCT at T0 at the edentulous site;
✓. No systemic disease, untreated periapical pathology or active periodontitis;
✓. Provision of written informed consent for the implant surgery by the patient or their legal guardian.
Exclusion criteria
✕. Uncontrolled systemic diseases or any bone-metabolism diseases;
What they're measuring
1
Apical Bone Height (ABH)
Timeframe: immediately postoperatively (T1), and 6 months postoperatively (T2)
2
Bone Height (BH)
Timeframe: immediately postoperatively (T1), and 6 months postoperatively (T2)
3
Endo-Sinus Bone Gain (ESBG)
Timeframe: immediately postoperatively (T1), and 6 months postoperatively (T2)
4
augmented volume (AV, mm³)
Timeframe: immediately postoperatively (T1), and 6 months postoperatively (T2)